Guyer William 4

What Happened William Guyer, Chief Development Officer of Corcept Therapeutics (CORT), received a derivative award of 140,000 shares on February 27, 2026. The award is recorded at an acquisition price of $0.00 (no immediate cash paid). This is a grant/award (not an open-market purchase or sale) and does not generate sale proceeds.

Key Details

• Transaction date: 2026-02-27; Form 4 filed: 2026-03-03.
• Transaction type: Grant / award of a derivative security (code A).
• Shares/units awarded: 140,000; reported acquisition price: $0.00 (total $0 reported).
• Vesting/exercise: Footnote F1 — the award will "exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period," subject to continued service.
• Shares owned after transaction: not specified in the provided filing.
• Remarks: power of attorney under which the form was signed is on file with the SEC.

Context This filing documents an executive equity grant that vests monthly over four years. Such awards are common for employee retention and do not by themselves signal immediate buying or selling in the market. Because this was an award (not a purchase or sale), there are no proceeds or immediate tax-withholding sales shown.